Notice of Intent to Sole Source – Cardinal Health, Inc.
ID: 25-003394Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Surgical and Medical Instrument Manufacturing (339112)

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/1e4b25de9153487ebe6b1d29a4bbbd40/view
Timeline
    Description

    The National Institutes of Health (NIH) intends to award a fixed-price purchase order to Cardinal Health, Inc. for the procurement of Floxuridine Vials, specifically for patient care at the NIH Clinical Center in Bethesda, Maryland. The requirement includes 10 units of Floxuridine for Injection, catalog number 0143-9270-01, which is exclusively distributed by Cardinal Health, Inc. in the United States, highlighting the critical nature of this medication for patient treatment. Interested parties may express their interest and capabilities to Kristin Nagashima at kristin.nagashima@nih.gov by February 10, 2025, at 4 PM EST, as this acquisition is being conducted under the Simplified Acquisition Procedures of the Federal Acquisition Regulation.

    Point(s) of Contact
    Kristin Nagashima
    kristin.nagashima@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent to Sole Source – Cardinal Health, Inc.
    Currently viewing
    Special Notice
    Similar Opportunities
    6505--ILLUCCIX PSMA VASD
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA), through the Network Contracting Office (NCO) 22, intends to award a sole source firm-fixed price contract to Cardinal Health 414, LLC for the procurement of Illuccix PSMA radioactive therapy injections. This procurement is justified under FAR 8.405-6(a)(1)(B), as only one source can provide the unique supplies necessary for treating prostate cancer patients undergoing Positron Emission Tomography (PET) imaging. The Illuccix PSMA injection is FDA approved for patients with prostate cancer, particularly for those whose cancer may have metastasized or recurred, making it a critical component in their treatment. Interested parties must submit a tailored capability statement and relevant company information by 10:00 AM PT on January 21, 2025, to Hestia.Sim@va.gov, as the VA reserves the right to proceed with Cardinal Health if no adequate responses are received.
    Hardy Diagnostic Reagents and Supplies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.
    Gore Medical branded stents (Brand Name restriction)
    Health And Human Services, Department Of
    The Department of Health and Human Services, National Institutes of Health seeks to procure specific medical devices for use in interventional radiology procedures. These are brand-restricted items, with the National Institute of Health specifying Gore Medical branded stents. The scope of work involves supplying several variants of two medical devices: Viatorr Tips Endo CX and Viabahn BX Balloon Expander Endo. The Viatorr Tips are measured in millimeters and vary in length, while the Viabahn BX Balloon Expanders are used in catheterization procedures. The medical devices are intended for minimally invasive procedures. The bill of materials provided outlines the exact models and quantities sought. Offerors must provide the following: 1 unit of Model PTB8105275, ID 00733132635016 - 8-10mmX5cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model PTB8107275, ID 00733132635030 - 8-10mmX7cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model PTB8108275, ID 00733132635047 - 8-10mmX8cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model BXB083901A, ID 00733132658718 - 8MMX39MM 7Fr 80CM Cath RP VIABAHN BX BALLOON EXP ENDO 1 unit of Model BXB085901A, ID 00733132658732 - 8MMX59MM 7Fr 80CM Cath RP VIABAHN BX BALLOON EXP ENDO Eligible applicants should be well-established surgical and medical instrument manufacturers (NAICS code 339112) with the ability to deliver the specified devices promptly. The evaluation of quotes will consider technical capability, price, and past performance. Quotes should be submitted to Lu Chang at lu-chang.lu@nih.gov by 5:00 PM EST on 08/01/2024, including the RFQ number (RFQ-CC-24-010258) in the subject line. Further inquiries can be directed to the same email address. This opportunity is a combined synopsis and solicitation issued under FAR Subpart 12.6. The resulting contract will be a firm fixed-price order.
    CONSUMABLES FOR HYDROPAC WATERING SYSTEM
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for consumables for the Hydropac watering system, as outlined in solicitation number RFQ-NIAID-25-2254249. The primary requirement includes a Hydropac Master Carton containing 72,000 valves and 36 rolls of pouch film, which are essential for the operational effectiveness of the NIH in managing infectious diseases. This procurement is structured under the Federal Acquisition Regulation (FAR) Subpart 12.6 for commercial items, emphasizing a brand name restriction to ensure compatibility with existing systems. Interested vendors must submit their offers by January 22, 2025, to Calvin Robinson at calvin.robinson@nih.gov, and must be registered in the System for Award Management (SAM) prior to award.
    NUcleic acid Linked Immuno-Sandwich Assay Reagents
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of NUcleic acid Linked Immuno-Sandwich Assay Reagents, aimed at enhancing biomarker discovery for neurodegenerative disease research at the Center for Alzheimer’s Disease and Related Dementias (CARD). The acquisition includes the Alamar NULISAseq Inflammation Panel, with a requirement for 30 units that must demonstrate high sensitivity in analyzing over 250 proteins from minimal sample volumes, ensuring compatibility with the ARGO proteomics platform. This procurement is critical for advancing research capabilities in the detection of biomarkers related to Alzheimer’s Disease and Related Dementias (ADRD). Interested vendors must submit their quotations by January 22, 2025, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@nida.nih.gov, and must comply with all specified federal regulations and provisions outlined in the solicitation.
    Notice of Intent to Sole Source – TheraDoc subscription
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) Clinical Center intends to award a firm fixed-price purchase order for subscription services related to the TheraDoc application, exclusively owned by Premier Healthcare LLC. This procurement aims to secure applications, support, maintenance, and training for the TheraDoc clinical surveillance solution, which is critical for enhancing healthcare delivery and patient safety. The acquisition will follow the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, allowing for a sole-source solicitation due to the unique nature of the services required. Interested parties may express their capabilities and submit comments to the NIH by November 21, 2024, with inquiries directed to Ryssa Nix at Ryssa.nix@nih.gov.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The objective of this procurement is to ensure the delivery of high-quality formulated drug products for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic development. This opportunity encompasses a wide range of services, including formulation development, manufacturing under current Good Manufacturing Practices (cGMP), and necessary testing to meet regulatory standards. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    GeminiBio GemCell TM Plus Xeno free Reagents.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a fixed-price contract for the supply of GeminiBio GemCell TM Plus Xeno free reagents, essential for the Center for Cellular Engineering's operations in Bethesda, Maryland. The procurement aims to secure a reliable source of reagents critical for manufacturing human cell and tissue-based products used in clinical trials, as the Center has validated GeminiBio's products for compatibility with its processes. This acquisition is vital to prevent treatment delays for patients involved in clinical trials, as switching vendors would necessitate costly and time-consuming requalification. Interested parties capable of providing similar products must submit a capability statement by January 26, 2025, to Emeka Onyejekwe at emeka.onyejekwe@nih.gov.
    Cambridge Isotope L-Glutamine
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide L-Glutamine enriched with stable isotope 13C for neuroscience research. The procurement aims to secure domestically manufactured chemicals that are essential for enhancing carbon-13 MR spectroscopy signals, which are critical for studying brain metabolism and measuring important metabolites. This initiative underscores the importance of maintaining a domestic supply of these chemicals to support ongoing research efforts at NIH and NIMH. Interested parties must submit their responses, including company information and capability statements, electronically to Joseph Kennedy at joseph.kennedy@nih.gov by January 22, 2025, as the anticipated contract duration is 12 months.
    SPEEDBioSystems TURBO293 Transfection Reagents
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a procurement contract with SPEED BioSystems, LLC for the acquisition of TURBO293 Transfection Reagents. The requirement includes 46 units of the TURBO293 TRANSFECTION REAGENT (20ML), which are critical for ongoing research and development activities at the Vaccine Research Center in Bethesda, Maryland. This procurement is being conducted on a sole-source basis due to SPEED BioSystems, LLC being the sole owner and developer of the required reagents, ensuring continuity and compatibility with existing protocols. Interested vendors may submit their capabilities statements to Jessica Emerson at jessica.emerson@nih.gov by the specified deadline for consideration, although the government is under no obligation to award a contract based on the responses received.